Related Experiment Videos
When and how to use angiotensin-converting enzyme inhibition in congestive heart failure
1Department of Cardiology, Central Hospital, Skövde, Sweden.
Insights
Angiotensin-converting enzyme (ACE) inhibitors effectively treat congestive heart failure (CHF) by reducing vascular resistance and improving hemodynamics. Clinical trials show ACE inhibitors significantly reduce mortality rates in CHF patients, making them a crucial therapy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) management often involves vasodilator therapy.
- Angiotensin-converting enzyme (ACE) inhibitors are recognized for their efficacy in treating CHF.
Purpose of the Study:
- To evaluate the effectiveness of ACE inhibitors in CHF patients.
- To assess the impact of ACE inhibitors on hemodynamic parameters and mortality.
Main Methods:
- Review of clinical data and studies on ACE inhibitor therapy in CHF.
- Analysis of hemodynamic responses (vascular resistance) at rest and during exercise.
- Examination of mortality data from trials like the Cooperative North Scandinavian Enalapril Survival Study.
Main Results:
- ACE inhibitors significantly reduce systemic and pulmonary vascular resistance, demonstrating both arterial and venodilating effects.
- A notable reduction in mortality rates for CHF patients treated with ACE inhibitors has been observed.
- Clinical response is not reliably predicted by heart failure etiology or acute hemodynamic measures.
Conclusions:
- ACE inhibitors are a first-choice vasodilator therapy for CHF, improving hemodynamics and reducing mortality.
- Individual patient trials are essential to determine efficacy due to variable responses.
- Captopril and enalapril are available options, with differing pharmacokinetic profiles influencing therapeutic choice.
Abstract:
Angiotensin-converting enzyme (ACE) inhibitors have been found effective in the treatment of congestive heart failure (CHF) and have been recommended as the first choice of vasodilator therapy by some observers. Favorable hemodynamic responses, apparent both at rest and during exercise, result from a considerable reduction in both systemic and pulmonary vascular resistance, apparently due to both the arterial and venodilating effects of these agents. In addition, the recently reported results of the Cooperative North Scandinavian Enalapril Survival Study demonstrate that ACE inhibitors reduce mortality rates in patients with CHF. The etiology of heart failure does not seem to predict clinical response to ACE inhibitors, nor do acute resting and exercise hemodynamic responses. A weak relation has been found between plasma renin activity and short-term hemodynamic and clinical responses, but this association is not evident over the long term. Therefore, a trial of therapy with ACE inhibitors is necessary to judge efficacy in an individual patient with advanced CHF symptoms. Two such agents--captopril and enalapril--are available. The former has a more rapid onset and shorter duration of action, whereas the latter may be given on a twice-daily basis, simplifying chronic therapy.